Hemoglobin in Prostate Cancer (ISSN 2753-8176 (online), DOI: 10.13140/RG.2.2.14314.59847

Hemoglobin in Prostate Cancer (ISSN 2753-8176 (online), DOI:10.13140/RG.2.2.14314.59847 Small report Ana Pedro (1) 1. Gwyntwr1386 Pharmacy, Regus Chester Business Park, Heronsway,Chester CH4 9QR, United Kingdom info@gwyntwr1386.com Prostate cancer is the second most common type of cancer in the world. Moreover, is the fifth leading cause of cancer-related mortality among men (1). About 99% of cases occur after age 50 (2). Early prostate cancer symptoms are often similar to those of benign prostatic hyperplasia and include frequent urination, nocturia (increased urination at night), difficulty starting and maintaining a steady stream of urine, hematuria (blood in the urine), dysuria (painful urination) as well as fatigue due to anemia, and bone pain (3). Like early cancer, metastic prostate cancer often causes bone pain, often in the vertebrae, pelvis, or ribs (4). By proteomics analysis of cell conditioned media precipitates, derived from cell culture of prostate cancer cells lines such as PC3, DU145, Vcap, and LNcap (fig.1), we found that all these cell lines secrete hemoglobin beta (HBB) with a range of different scores (1 to 4), being that LNcap (lymph node metastasis) only secretes HBB and with a low score (1). Both PC3 (bone metastasis, negative to androgen receptor) and DU145 (brain metastasis) secrete hemoglobin alpha with a low score (1). Moreover, Vcap (bone metastasis, wild type (WT) androgen receptor), additionally expresses hemoglobin delta (HBD) with a level 2 score. Finally, PC3 also secretes hemoglobin gamma-2 (HG2) with a low score (1) (5-8) Methods Proteomic analysis was performed at the Rockefeller University, Proteomics Center as described in Hamidi et al., 2017 (9). Only proteins with Mascot scores of approximately 90 or >90 were considered (10) The proteomic analysis excel files and each correspondent sample details were generously and kindly shared and donated by Dr. David Lyden, Weill Cornell Medical College, New York, USA. Original data files can be found at https://zenodo.org/record/7653082#.Y_DuxXbP3IU References 1. Luining WI, Cysouw MC, Meijer D, Hendrikse NH, Boellaard R, Vis AN, Oprea-Lager DE (February 2022)."Targeting PSMA Revolutionizes the Role of Nuclear Medicine in Diagnosis and Treatment of Prostate Cancer". 2. Chapter 5.11".World Cancer Report. World Health Organization. 2014.ISBN 978-9283204299. 3. Leslie SW, Soon-Sutton TL, Sajjad H, Siref LE. Prostate Cancer. 2020 Oct 28. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; PMID 29261872. 4. Liu Z, Murphy SF, Huang J, Zhao L, Hall CC, Schaeffer AJ, et al. (July 2020). "A novel immunocompetent model of metastatic prostate cancer-induced bone pain". The Prostate. 80 (10): 782–794. 5. Wu X et al (2013). Current mouse and cell models in prostate cancer research. Endocr Relat Cancer. 2013 August ; 20(4): . doi:10.1530/ERC-12-0285. 6. Basak D et al (2022). Preclinical and Clinical Research Models of Prostate Cancer: A Brief Overview (review). Life 2022, 12, 1607. https://doi.org/10.3390/life12101607 7. Quiroz-Munoz M et al (2019). Mechanisms of Osteoblastic Bone Metastasis in Prostate Cancer: Role of Prostatic Acid Phosphatase. March 2019 | Vol. 3, Iss. 3 doi: 10.1210/js.2018-00425 | Journal of the Endocrine Society | 655–664 8. Lange et al (2020). Xenograft-derived mRNA/miR and protein interaction networks of systemic dissemination in human prostate cancer. European Journal of Cancer 137 (2020) 93e107 9. https://www.biorxiv.org/content/10.1101/202291v1 10.

https://f1000research.com/articles/7-283